Moderna agreed to a major settlement with Arbutus Biopharma and Roivant’s Genevant, paying $950 million upfront to resolve patent claims tied to its Covid-19 vaccine, with contingent payments that could push the total to as much as $2.25 billion. The settlement ends years of litigation over delivery- and lipid-nanoparticle–related patents and removes a strategic overhang for Moderna’s commercial and R&D planning. Roivant and Arbutus will receive an immediate cash payment and potential further proceeds depending on appellate outcomes and government indemnification issues. The deal transfers significant legal risk off Moderna’s balance sheet and clarifies licensing exposure for mRNA vaccine makers. Industry participants say the settlement could recalibrate licensing markets for LNP technologies used broadly across nucleic acid therapeutics. Legal experts note the scale of the payout underscores the commercial value of delivery-platform patents for mRNA vaccines and gene medicines. The settlement may influence ongoing filings and valuations of companies that rely on similar lipid-nanoparticle or formulation intellectual property, accelerating licensing talks and reshaping how platform IP is monetized.